Related Experiment Video
Updated: Jul 9, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Antiangiogenic agents for the treatment of glioblastoma
Elizabeth R Gerstner1, Dan G Duda, Emmanuelle di Tomaso
11Massachusetts General Hospital Cancer Center and Harvard Medical School, Department of Neurology, Boston, Massachusetts, USA.
Abstract:
Glioblastomas are highly vascularized and, therefore, antiangiogenic agents are increasingly being explored as therapeutic options. This review summarizes the present data on antiangiogenic agents in glioblastoma treatment. The angiogenic pathway in gliomas and the proposed mechanisms of antiangiogenic agents are reviewed briefly, and details of the drugs in clinical trial are provided. In addition to their effects on blood vessels, these agents also have potent antiedema effects that may have therapeutic benefit. The review concludes with a discussion of the role of biomarkers and neuroimaging in the assessment of tumor response. Although preliminary studies of these drugs in glioblastoma have been promising, larger prospective trials that include survival as an end point will be required to determine the ultimate utility of this class of agents. It seems likely that a combination of antiangiogenesis agents with other cytotoxic therapies will be required to achieve maximal efficacy.
Insights
Antiangiogenic agents show promise in treating glioblastoma by targeting blood vessel growth and reducing edema. Further trials are needed to confirm their efficacy, likely in combination with other therapies.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Glioblastomas are highly vascular tumors.
- Antiangiogenic agents are being investigated for glioblastoma treatment.
- These agents target the tumor's blood supply.
Purpose of the Study:
- To review current data on antiangiogenic agents for glioblastoma.
- To discuss the mechanisms and clinical trials of these agents.
- To explore the role of biomarkers and neuroimaging in assessing treatment response.
Main Methods:
- Literature review of antiangiogenic agents in glioblastoma.
- Summary of preclinical and clinical data.
- Discussion of drug mechanisms, clinical trials, and response assessment.
Main Results:
- Antiangiogenic agents demonstrate anti-vascular and anti-edema effects.
- Preliminary studies show promising results in glioblastoma.
- Biomarkers and neuroimaging are crucial for evaluating tumor response.
Conclusions:
- Antiangiogenic agents offer potential therapeutic benefits for glioblastoma.
- Larger prospective trials are necessary to establish survival benefits.
- Combination therapy with cytotoxic agents may enhance efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis